Table of Contents
Advances in Chemistry
Volume 2014, Article ID 471950, 13 pages
Research Article

Synthesis and Characterization of Tolvaptan Impurities

R and D, Mylan Laboratories Ltd., Plot No. 31, 32, 33 and 34 A ANRICH Industrial Estate, Bollaram, Jinnaram, Medak, Andhra Pradesh 502325, India

Received 12 May 2014; Accepted 26 June 2014; Published 10 July 2014

Academic Editor: Atsushi Ohtaka

Copyright © 2014 Madhuresh Kumar Sethi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. L. Lohr, T. R. Sharp, K. M. Alsante, and T. D. Hatajik, “Isolation and identification of process related impurities and degradation products from pharmaceutical drug candidates. Part 1,” American Pharmaceutical Review, vol. 4, no. 1, pp. 70–78, 2001. View at Google Scholar
  2. S. Görög, “Chemical and analytical characterization of related organic impurities in drugs,” Analytical and Bioanalytical Chemistry, vol. 377, no. 5, pp. 852–862, 2003. View at Publisher · View at Google Scholar
  3. N. R. Rao, S. S. Mani Kiran, and N. L. Prasanthi, “Pharmaceutical impurities: an overview,” Indian Journal of Pharmaceutical Education and Research, vol. 44, no. 3, pp. 302–306, 2010. View at Google Scholar
  4. S. Ahuja, Impurities Evaluation of Pharmaceuticals, Mercel Dekker, New York, NY, USA, 1998.
  5. R. W. Schrier, P. Gross, M. Gheorghiade et al., “Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia,” The New England Journal of Medicine, vol. 355, no. 20, pp. 2099–2112, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. J. K. Ghali, B. Hamad, U. Yasothan, and P. Kirkpatrick, “Tolvaptan,” Nature Reviews Drug Discovery, vol. 8, no. 8, pp. 611–612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. G. R. Belum, V. R. Belum, S. K. Chaitanya Arudra, and B. S. N. Reddy, “The Jarisch-Herxheimer reaction: revisited,” Travel Medicine and Infectious Disease, vol. 11, no. 4, pp. 231–237, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. H. D. Zmily, S. Daifallah, and J. K. Ghali, “Tolvaptan, hyponatremia, and heart failure,” International Journal of Nephrology and Renovascular Disease, vol. 4, pp. 57–71, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. M. N. Ferguson, “Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan,” Cardiology in Review, vol. 18, no. 6, pp. 313–321, 2010. View at Publisher · View at Google Scholar
  10. H. Ogawa, H. Miyamoto, K. Kondo et al., US5258510, 1993.
  11. K. Kondo, H. Ogawa, H. Yamashita et al., “7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5- tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist,” Bioorganic and Medicinal Chemistry, vol. 7, no. 8, pp. 1743–1754, 1999. View at Publisher · View at Google Scholar · View at Scopus